B3041001: a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of Multistem (Pf-05285401) in Subjects with Moderate to Severe Ulcerative Colitis

-
Investigator: Jonathan Terdiman, MD
Sponsor: Pfizer

Location(s): United States

Description

PF-05285401, also known as MultiStem®, is a cell-based, biological therapy under development for the treatment of ulcerative colitis (UC). MultiStem is manufactured from human stem cells obtained from adult bone marrow. The study is designed to evaluate the safety and tolerability of multiple intravenous doses of MultiStem in moderate-to-severe ulcerative colitis and to study the efficacy of multiple intravenous doses of MultiStem in moderate-to-severe ulcerative colitis.